Aurobindo Pharma Ltd said on Thursday it would make and sell U.S.-based COVAXX's COVID-19 vaccine candidate for supply in India and to the United Nations Children's Fund (UNICEF) under a licensing deal.The Indian drugmaker also has non-exclusive rights to sell the shot — which is currently undergoing an early-stage trial — in certain other emerging markets, the Hyderabad-based company said in an exchange filing.Also Read | Inside the farmer disquiet at Delhi’s doorstepCOVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the United States.The companies said the shot uses normal refrigeration as opposed to the freezing.
Read more on livemint.com